Vigonvita Life Sciences Co., Ltd. (HKG:2630)

Vigonvita Life Sciences Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023
Period Ending	Mar 5, 2026	Dec 31, 2024	Dec 31, 2023
Debt / Equity Ratio	2.97	2.97	1.71
Debt / EBITDA Ratio	-	-	13.34
Net Debt / Equity Ratio	2.10	2.10	1.20
Net Debt / EBITDA Ratio	-1.61	-1.61	15.93
Net Debt / FCF Ratio	-1.58	-1.58	-4.01
Asset Turnover	0.02	0.02	-
Inventory Turnover	1.11	1.11	-
Quick Ratio	0.46	0.46	0.56
Current Ratio	0.50	0.50	0.58
Return on Equity (ROE)	-132.51%	-132.51%	-
Return on Assets (ROA)	-18.15%	-18.15%	-
Return on Capital Employed (ROCE)	-50.40%	-50.40%	1.90%
Buyback Yield / Dilution	-	-0.69%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.